hydrazine has been researched along with Hematologic Malignancies in 10 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (20.00) | 29.6817 |
| 2010's | 4 (40.00) | 24.3611 |
| 2020's | 4 (40.00) | 2.80 |
| Authors | Studies |
|---|---|
| Garzon, R; Lapalombella, R; Walker, JS | 1 |
| Benkova, K; Hajek, R; Jelinek, T; Mihalyova, J | 1 |
| Azmi, AS; Mohammad, RM; Uddin, MH | 1 |
| Locatelli, F; Merli, P; Quintarelli, C; Strocchio, L | 1 |
| Bandara, G; Desai, A; Komarow, HD; Metcalfe, DD; Muñoz-Cano, R; Olivera, A; Tobío, A; Yin, Y | 1 |
| Balduini, CL; Pecci, A; Rodeghiero, F | 1 |
| Andolina, JR; Becker, M; Chen, Y; Constine, LS; Dawson, KL; DeBolt, J; Erickson-Miller, CL; Friedberg, J; Hyrien, O; Johnson, BM; Liesveld, JL; Milner, LA; Phillips, GL; Smudzin, T | 1 |
| Alvarado, Y; Giles, FJ; Kelly, KR; Swords, R | 1 |
| Arning, M; Bailey, CK; Brainsky, A; Bussel, JB; Cheng, G; Meyer, O; Saleh, MN | 1 |
| Tear, S | 1 |
5 review(s) available for hydrazine and Hematologic Malignancies
| Article | Year |
|---|---|
Selinexor for advanced hematologic malignancies.
Topics: Cell Line, Tumor; Hematologic Neoplasms; Humans; Hydrazines; Triazoles | 2020 |
Selinexor, selective inhibitor of nuclear export: Unselective bullet for blood cancers.
Topics: Active Transport, Cell Nucleus; Antineoplastic Agents; Disease Management; Exportin 1 Protein; Hematologic Neoplasms; Humans; Hydrazines; Karyopherins; Molecular Targeted Therapy; Prognosis; Receptors, Cytoplasmic and Nuclear; Treatment Outcome; Triazoles | 2021 |
The nuclear export protein XPO1 - from biology to targeted therapy.
Topics: Antineoplastic Agents; Cell Line, Tumor; Dexamethasone; Drug Resistance, Neoplasm; Exportin 1 Protein; Hematologic Neoplasms; Humans; Hydrazines; Karyopherins; Lymphoma, Large B-Cell, Diffuse; Molecular Targeted Therapy; Receptors, Cytoplasmic and Nuclear; Triazoles | 2021 |
The role of interferon-gamma and its signaling pathway in pediatric hematological disorders.
Topics: Animals; Antineoplastic Agents; Benzoates; Child; Drug Discovery; Hematologic Neoplasms; Hematopoiesis; Hematopoietic Stem Cell Transplantation; Humans; Hydrazines; Immunotherapy; Interferon-gamma; Janus Kinases; Nitriles; Pyrazoles; Pyrimidines; Signal Transduction | 2021 |
Thrombopoietin receptor agonists in hereditary thrombocytopenias.
Topics: Benzoates; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Genetic Association Studies; Genetic Heterogeneity; Genetic Predisposition to Disease; Hematologic Neoplasms; Humans; Hydrazines; Primary Myelofibrosis; Purpura, Thrombocytopenic, Idiopathic; Pyrazoles; Receptors, Fc; Receptors, Thrombopoietin; Recombinant Fusion Proteins; Risk; Thrombocytopenia; Thrombophilia; Thrombopoiesis; Thrombopoietin | 2018 |
2 trial(s) available for hydrazine and Hematologic Malignancies
| Article | Year |
|---|---|
A phase 1 trial of eltrombopag in patients undergoing stem cell transplantation after total body irradiation.
Topics: Adult; Aged; Benzoates; Dose-Response Relationship, Drug; Female; Hematologic Neoplasms; Humans; Hydrazines; Male; Middle Aged; Pyrazoles; Stem Cell Transplantation; Thrombocytopenia; Transplantation Conditioning; Transplantation, Autologous; Whole-Body Irradiation; Young Adult | 2013 |
Safety and efficacy of eltrombopag for treatment of chronic immune thrombocytopenia: results of the long-term, open-label EXTEND study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Benzoates; Blood Platelets; Bone Marrow Diseases; Chronic Disease; Female; Hematologic Neoplasms; Hemorrhage; Humans; Hydrazines; Liver Diseases; Male; Middle Aged; Platelet Count; Purpura, Thrombocytopenic, Idiopathic; Pyrazoles; Receptors, Thrombopoietin; Treatment Outcome; Young Adult | 2013 |
3 other study(ies) available for hydrazine and Hematologic Malignancies
| Article | Year |
|---|---|
Targeting Sphingosine Kinase Isoforms Effectively Reduces Growth and Survival of Neoplastic Mast Cells With D816V-KIT.
Topics: Adamantane; Animals; Apoptosis; Carcinogenesis; Cell Proliferation; Cell Survival; DNA Repair; Hematologic Neoplasms; Humans; Hydrazines; Mast Cells; Mastocytosis; Mice; Mice, Knockout; Mutation; Phosphotransferases (Alcohol Group Acceptor); Protein Isoforms; Proto-Oncogene Proteins c-kit; Pyrazoles; Pyridines; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2018 |
Clinical activity of laromustine (Onrigin™) in hematologic malignancies.
Topics: Animals; Antineoplastic Agents, Alkylating; Clinical Trials as Topic; Drug Evaluation, Preclinical; Hematologic Neoplasms; Humans; Hydrazines; Sulfonamides | 2009 |
American Society of Hematology--48th Annual Meeting and Exposition. Therapeutic approaches for hematological cancers. 9-12 December 2006 Orlando, FL, USA.
Topics: Animals; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Clinical Trials, Phase I as Topic; Dacarbazine; Hematologic Neoplasms; Hematology; Humans; Hydrazines; Leukemia, Myeloid; Multiple Myeloma; Proteasome Endopeptidase Complex; Proto-Oncogene Proteins c-kit; Sulfonamides; Temozolomide | 2007 |